COVID-19 Evidence Alerts
from McMaster PLUSTM

Current best evidence for clinical care (more info)

COVID-19 Evidence Alerts needs your support. If our service is of value to you, please consider donating to keep it going. Learn more Donate now

Treatment Pal R, Banerjee M, Mukherjee S, et al. Dipeptidyl peptidase-4 inhibitor use and mortality in COVID-19 patients with diabetes mellitus: an updated systematic review and meta-analysis. Ther Adv Endocrinol Metab. 2021 Feb 20;12:2042018821996482. doi: 10.1177/2042018821996482. eCollection 2021.
Abstract

Background: Few observational studies have shown a beneficial effect of dipeptidyl peptidase-4 inhibitors (DPP4i) in patients with coronavirus disease 2019 (COVID-19), although results are not consistent. The present systematic review and meta-analysis was undertaken to provide a precise summary of the effect of DPP4i use (preadmission or in-hospital) and mortality in COVID-19 patients with diabetes mellitus (DM).

Methods: PubMed and Google Scholar databases were systematically searched using appropriate keywords to 4 January 2021, to identify observational studies reporting mortality in COVID-19 patients with DM using DPP4i versus those not using DPP4i. Preadmission and in-hospital use of DPP4i were considered. Study quality was assessed using the Newcastle-Ottawa Scale. Unadjusted and adjusted pooled odds ratio (OR) with 95% confidence intervals (CIs) were calculated. Subgroup analysis was performed for studies reporting preadmission and in-hospital use of DPP4i.

Results: We identified nine observational studies of high quality pooling data retrieved from 7008 COVID-19 patients with DM. The pooled analysis of unadjusted and adjusted data did not show any significant association between DPP4i use and mortality in COVID-19 patients with DM. However, on subgroup analysis, we found that in-hospital (and not preadmission) DPP4i use was associated with reduced mortality (unadjusted OR 0.37, 95% CI 0.23, 0.58, p < 0.0001, I2 = 0% and adjusted OR 0.27, 95% CI 0.13, 0.55, p = 0.0003, I2 = 12%).

Conclusions: In-hospital use of DPP4i is associated with a significant reduction in COVID-19 mortality. Hence, it would be prudent to initiate or continue DPP4i in COVID-19 patients with DM if not contraindicated.

Ratings
Discipline / Specialty Area Score
Endocrine
Hospital Doctor/Hospitalists
Internal Medicine
Comments from MORE raters

Endocrine rater

This is a good study that reviewed 9 observational studies and showed that DPP-IV inhibitors decrease the risk of COVID-19 mortality.

Hospital Doctor/Hospitalists rater

I can't dispel the concern that there might be a sample selection bias in each study. However, the results of the present meta-analysis are convincing enough to go ahead with conducting RCTs.

Internal Medicine rater

There was no association between DPP4-inhibitors and survival benefit. The authors concluded this from the af subgroup analysis of this observational study; I disagree with this. We need a RCT to conclude whether patients with Covid-19 benefit from treatment with DPP4-inhibitors or not.